Article citationsMore>>

M. Sato, T. Yamashita, M. Ohkura, Y. Osai, A. Sato, T. Takada, H. Matsusaka, I. Ono, Y. Tamura, N. Sato, Y. Sasaki, A. Ito, H. Honda, K. Wakamatsu, S. Ito and K. Jimbow, “N-Propionyl-Cysteaminyl-Phenol-Magnetite Con- jugate (NPrCAP/M) Is a Nanoparticle for the Targeted Growth Suppression of Melanoma Cells,” Journal of Investigative Dermatology, Vol. 129, 2009, pp. 2233-2241. doi:10.1038/jid.2009.39

has been cited by the following article:

• TITLE: Conjugation of Magnetite Nanoparticles with Melanogenesis Substrate, NPrCAP Provides Melanoma Targeted, in Situ Peptide Vaccine Immunotherapy through HSP Production by Chemo-Thermotherapy

  AUTHORS: Kowichi Jimbow, Yasuaki Tamura, Akihiro Yoneta, Takafumi Kamiya, Ichiro Ono, Toshiharu Yamashita, Akira Ito, Hiroyuki Honda, Kazumasa Wakamatsu, Shosuke Ito, Satoshi Nohara, Eiichi Nakayama, Takeshi Kobayashi

  KEYWORDS: Melanogenesis; Chemo-Thermo-Immunotherapy; Nanomedicine; Melanoma; Magnetite Nanoparticles

  JOURNAL NAME: Journal of Biomaterials and Nanobiotechnology, Vol.3 No.2, April 28, 2012

  ABSTRACT: In order to develop melanoma-targeted in situ peptide vaccine immunotherapy, magnetite nanoparticles were conjugated with a melanogenesis substrate, N-propionyl cysteaminylphenol (NPrCAP). Magnetite nanoparticles introduced thermotherapy which caused non-apoptotic cell death and generation of heat shock protein (HSP) upon exposure to alternating magnetic field (AMF). NPrCAP was expected to develop a melanoma-targeted therapeutic drug because of its selective incorporation into melanoma cells and production of highly reactive free radicals, that result in not only oxidative stress but also apoptotic cell death by reacting with tyrosinase.